» Articles » PMID: 24473089

Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2014 Jan 30
PMID 24473089
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Since its original identification as a leukocyte gelatinase/type V collagenase and tumour type IV collagenase, gelatinase B/matrix metalloproteinase (MMP)-9 is now recognised as playing a central role in many aspects of tumour progression. In this review, we relate current concepts concerning the many ways in which gelatinase B/MMP-9 influences tumour biology. Following a brief outline of the gelatinase B/MMP-9 gene and protein, we analyse the role(s) of gelatinase B/MMP-9 in different phases of the tumorigenic process, and compare the importance of gelatinase B/MMP-9 source in the carcinogenic process. What becomes apparent is the importance of inflammatory cell-derived gelatinase B/MMP-9 in tumour promotion, early progression and triggering of the "angiogenic switch", the integral relationship between inflammatory, stromal and tumour components with respect to gelatinase B/MMP-9 production and activation, and the fundamental role for gelatinase B/MMP-9 in the formation and maintenance of tumour stem cell and metastatic niches. It is also apparent that gelatinase B/MMP-9 plays important tumour suppressing functions, producing endogenous angiogenesis inhibitors, promoting inflammatory anti-tumour activity, and inducing apoptosis. The fundamental roles of gelatinase B/MMP-9 in cancer biology underpins the need for specific therapeutic inhibitors of gelatinase B/MMP-9 function, the use of which must take into account and substitute for tumour-suppressing gelatinase B/MMP-9 activity and also limit inhibition of physiological gelatinase B/MMP-9 function.

Citing Articles

Deciphering the oncogenic influence of : Implications of matrix metalloproteinase activation.

Nambiar J, Venugopal M, Shaji S, Bose C, Rajeev A, Kalliadan S Heliyon. 2025; 11(4):e42538.

PMID: 40028520 PMC: 11870157. DOI: 10.1016/j.heliyon.2025.e42538.


Significant Association of Matrix Metalloproteinase-9 Polymorphisms With Triple Negative Breast Cancer Risk.

Hung C, Wang Y, Shih H, Liu C, He J, Chen J Cancer Genomics Proteomics. 2025; 22(2):258-270.

PMID: 39993804 PMC: 11880922. DOI: 10.21873/cgp.20500.


Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer.

Zhang X, Ren X, Zhang S, Wang Y Exp Ther Med. 2024; 28(6):441.

PMID: 39583246 PMC: 11582528. DOI: 10.3892/etm.2024.12730.


Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway.

Sivaganesh V, Ta T, Peethambaran B Int J Mol Sci. 2024; 25(13).

PMID: 39000112 PMC: 11241829. DOI: 10.3390/ijms25137003.


Association of Genotypes With Nasopharyngeal Carcinoma Risk.

Chen C, Shih L, Hsu S, Tien H, Liu Y, Wang Y In Vivo. 2024; 38(4):1731-1739.

PMID: 38936920 PMC: 11215630. DOI: 10.21873/invivo.13623.


References
1.
Hollenbeck S, Sakakibara K, Faries P, Workhu B, Liu B, Kent K . Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J Surg Res. 2004; 120(2):288-94. DOI: 10.1016/j.jss.2004.01.005. View

2.
Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R . The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer. 2000; 87(3):336-42. View

3.
Jiang Y, Muschel R . Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res. 2002; 62(6):1910-4. View

4.
Vandooren J, Van den Steen P, Opdenakker G . Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013; 48(3):222-72. DOI: 10.3109/10409238.2013.770819. View

5.
Ghosh S, Basu M, Roy S . ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem. 2012; 287(18):15001-15. PMC: 3340257. DOI: 10.1074/jbc.M111.284034. View